Sufentanil Citrate (Dzuveo®) HTA ID: 23062

Assessment Status Rapid Review Complete
Drug Sufentanil Citrate
Brand Dzuveo®
Indication For the management of acute moderate to severe pain in adult patients
Assessment Process
Rapid review commissioned 02/10/2023
Rapid review resubmission required 04/12/2023
Rapid review completed 22/12/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that sufentanil citrate not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in
the Health (Pricing and Supply of Medical Goods) Act 2013.